carmegliptin

Known as: (4S)-1-[(2S,3S,11bS)-2-amino-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1- a]isoquinolin-3-yl]-4-(fluoromethyl)pyrrolidin-2-one 
A potent, long-acting, selective, orally bioavailable, pyrrolidinone-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2014
01220102014

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
PURPOSE The purpose of this exercise was to explore the utility of allometric scaling approach for the prediction of intravenous… (More)
Is this relevant?
2014
2014
OBJECTIVE The primary objective of this study was to investigate the interaction potential of carmegliptin with P-glycoprotein… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2012
2012
Three-dimensional pharmacophore hypothesis was established based on a set of known DPP-IV inhibitor using PharmaGist software… (More)
Is this relevant?
2010
2010
Design, synthesis, and SAR are described for a class of DPP-IV inhibitors based on aminobenzo[a]quinolizines with non-aromatic… (More)
Is this relevant?
2010
2010
The pharmacokinetics and excretion of carmegliptin, a novel dipeptidyl peptidase IV inhibitor, were examined in rats, dogs, and… (More)
Is this relevant?